专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2017184562A1 CMV NEUTRALIZING ANTIGEN BINDING PROTEINS 审中-公开
标题翻译： CMV中和抗原结合蛋白
公开(公告)号：WO2017184562A1
公开(公告)日：2017-10-26
申请号：PCT/US2017/028062
申请日：2017-04-18
申请人： MERCK SHARP & DOHME CORP. , THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM , FU, Tong-Ming , TANG, Aimin , WANG, Dai , AN, Zhiqiang , ZHANG, Ningyan , HA, Sha
发明人： FU, Tong-Ming , TANG, Aimin , WANG, Dai , AN, Zhiqiang , ZHANG, Ningyan , HA, Sha
IPC分类号： A61K39/00 , A61K39/245 , A61K39/395 , A61K39/42 , C12N7/00 , C12P21/00
摘要： The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (CMV). The antigen binding proteins of the invention are useful as a prophylactic and/or therapeutic agent for preventing and/or treating CMV infections in a patient in need thereof. Also encompassed by the invention are pharmaceutical compositions comprising the antigen binding proteins of the invention and a pharmaceutically acceptable carrier. The invention further relates to methods of using the antigen binding proteins and pharmaceutical compositions of the invention for the prevention or treatment of CMV infection in patients in need thereof.
摘要翻译：本发明涉及抗原结合蛋白，其包括但不限于特异性结合并优选中和人巨细胞病毒（CMV）的单克隆抗体及其抗原结合片段。本发明的抗原结合蛋白可用作在有此需要的患者中预防和/或治疗CMV感染的预防和/或治疗剂。本发明还涵盖包含本发明的抗原结合蛋白和药学上可接受的载体的药物组合物。本发明进一步涉及使用本发明的抗原结合蛋白和药物组合物在有需要的患者中预防或治疗CMV感染的方法。

2. 发明申请

WO2017075124A1 ANTIBODY NEUTRALIZING HUMAN RESPIRATORY SYNCYTIAL VIRUS 审中-公开
标题翻译：抗体中和人呼吸道合胞病毒
公开(公告)号：WO2017075124A1
公开(公告)日：2017-05-04
申请号：PCT/US2016/058975
申请日：2016-10-27
申请人： MERCK SHARP & DOHME CORP. , VORA, Kalpit, A. , COX, Kara, S. , TANG, Aimin , CHEN, Zhifeng , DISTEFANO, Daniel , ZHANG, Lan , SU, Hua-Poo
发明人： VORA, Kalpit, A. , COX, Kara, S. , TANG, Aimin , CHEN, Zhifeng , DISTEFANO, Daniel , ZHANG, Lan , SU, Hua-Poo
IPC分类号： C07K16/10 , A61P31/14
CPC分类号： C07K16/1027 , A61K39/42 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/14 , C07K2317/21 , C07K2317/34 , C07K2317/41 , C07K2317/524 , C07K2317/565 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.
摘要翻译：本发明涉及具有高抗RSV中和滴度的单克隆抗体。本发明进一步提供了编码本发明抗体的分离的核酸和用其转化的宿主细胞。本发明进一步提供了采用本发明的抗体和核酸的诊断，预防和治疗方法，特别是作为婴幼儿和老年人的被动免疫治疗剂。

3. 发明申请

WO2010014567A2 VARIANT HCMV PP65, IE1, AND IE2 POLYNUCLEOTIDES AND USES THEREOF 审中-公开
标题翻译： VARIANT HCMV PP65，IE1和IE2多核苷酸及其用途
公开(公告)号：WO2010014567A2
公开(公告)日：2010-02-04
申请号：PCT/US2009/051895
申请日：2009-07-28
申请人： MERCK & CO., INC. , FU, Tong-Ming , CASIMIRO, Danilo, R. , FREED, Daniel, C. , TANG, Aimin
发明人： FU, Tong-Ming , CASIMIRO, Danilo, R. , FREED, Daniel, C. , TANG, Aimin
IPC分类号： A61K48/00
CPC分类号： C07K14/005 , C12N2710/16122
摘要： The present invention relates to compositions and methods to elicit or enhance cell-mediated immunity against HCMV infection by providing polynucleotides encoding variant HCMV pp65, IE1, and IE2 proteins, and fusion proteins thereof. The present invention also provides recombinant vectors including, but not limited to, adenovirus and plasmid vectors comprising said polynucleotides and host cells comprising said recombinant vectors. Also provided herein are purified forms of the variant HCMV pp65, IE1, and IE2 proteins described herein, and fusion proteins. The variant HCMV proteins, and fusion proteins thereof, are useful as vaccines for the protection from and/or treatment of HCMV infection. Said vaccines are useful as a monotherapy or a part of a therapeutic regime, said regime comprising administration of a second vaccine such as a polynucleotide, cell-based, protein or peptide-based vaccine.
摘要翻译：本发明涉及通过提供编码变体HCMV pp65，IE1和IE2蛋白的多核苷酸及其融合蛋白来引发或增强针对HCMV感染的细胞介导的免疫的组合物和方法。本发明还提供了重组载体，包括但不限于包含所述多核苷酸的腺病毒和质粒载体以及包含所述重组载体的宿主细胞。本文还提供了本文所述的变体HCMV pp65，IE1和IE2蛋白的纯化形式以及融合蛋白。变体HCMV蛋白及其融合蛋白可用作针对HCMV感染的保护和/或治疗的疫苗。所述疫苗可用作单一疗法或治疗方案的一部分，所述方案包括施用第二种疫苗，例如多核苷酸，基于细胞的，基于蛋白质或基于肽的疫苗。

4. 发明申请

WO2009114335A2 PD-1 BINDING PROTEINS 审中-公开
标题翻译： PD-1结合蛋白
公开(公告)号：WO2009114335A2
公开(公告)日：2009-09-17
申请号：PCT/US2009/035825
申请日：2009-03-03
申请人： MERCK & CO., INC. , FINNEFROCK, Adam, C. , FU, Tong-Ming , FREED, Daniel, C. , CASIMIRO, Danilo, R. , LI, Fengsheng , TANG, Aimin
发明人： FINNEFROCK, Adam, C. , FU, Tong-Ming , FREED, Daniel, C. , CASIMIRO, Danilo, R. , LI, Fengsheng , TANG, Aimin
IPC分类号： A61K39/395
CPC分类号： C07K16/2896 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/92 , C07K2319/30
摘要： The present invention features PD-1 binding proteins, a subset of which inhibits binding of PD-L1 to the PD-1 receptor. These binding proteins can be employed to modulate the immune system through the manipulation of the PD-1 signaling pathway, enhancing host immunity to treat infections and cancer.
摘要翻译：本发明的特征在于PD-1结合蛋白，其一部分抑制PD-L1与PD-1受体的结合。这些结合蛋白可用于通过操纵PD-1信号传导途径来调节免疫系统，增强宿主免疫治疗感染和癌症。

5. 发明公开

EP2262837A2 PD-1 BINDING PROTEINS 审中-公开
标题翻译： PD-1结合蛋白
公开(公告)号：EP2262837A2
公开(公告)日：2010-12-22
申请号：EP09719690.1
申请日：2009-03-03
申请人： Merck Sharp & Dohme Corp.
发明人： FINNEFROCK, Adam, C. , FU, Tong-Ming , FREED, Daniel, C. , CASIMIRO, Danilo, R. , LI, Fengsheng , TANG, Aimin
IPC分类号： C07K16/28 , C12P21/08
CPC分类号： C07K16/2896 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/92 , C07K2319/30
摘要： The present invention features PD-1 binding proteins, a subset of which inhibits binding of PD-L1 to the PD-1 receptor. These binding proteins can be employed to modulate the immune system through the manipulation of the PD-1 signaling pathway, enhancing host immunity to treat infections and cancer.

6. 发明公开

EP3368562A1 ANTIBODY NEUTRALIZING HUMAN RESPIRATORY SYNCYTIAL VIRUS 审中-公开
公开(公告)号：EP3368562A1
公开(公告)日：2018-09-05
申请号：EP16790858.1
申请日：2016-10-27
申请人： Merck Sharp & Dohme Corp.
发明人： VORA, Kalpit, A. , COX, Kara, S. , TANG, Aimin , CHEN, Zhifeng , DISTEFANO, Daniel , ZHANG, Lan , SU, Hua-Poo
IPC分类号： C07K16/10 , A61P31/14
CPC分类号： C07K16/1027 , A61K39/42 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/14 , C07K2317/21 , C07K2317/34 , C07K2317/41 , C07K2317/524 , C07K2317/565 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.

7. 发明公开

EP2313503A2 VARIANT HCMV PP65, IE1, AND IE2 POLYNUCLEOTIDES AND USES THEREOF 审中-公开
标题翻译： VARIANT HCMV病毒pp65，IE1 IE2和多核苷酸及其用途
公开(公告)号：EP2313503A2
公开(公告)日：2011-04-27
申请号：EP09803451.5
申请日：2009-07-28
申请人： Merck Sharp & Dohme Corp.
发明人： FU, Tong-Ming , CASIMIRO, Danilo, R. , FREED, Daniel, C. , TANG, Aimin
IPC分类号： C12N15/00 , A61K39/12 , A61K39/25
CPC分类号： C07K14/005 , C12N2710/16122
摘要： The present invention relates to compositions and methods to elicit or enhance cell-mediated immunity against HCMV infection by providing polynucleotides encoding variant HCMV pp65, IE1, and IE2 proteins, and fusion proteins thereof. The present invention also provides recombinant vectors including, but not limited to, adenovirus and plasmid vectors comprising said polynucleotides and host cells comprising said recombinant vectors. Also provided herein are purified forms of the variant HCMV pp65, IE1, and IE2 proteins described herein, and fusion proteins. The variant HCMV proteins, and fusion proteins thereof, are useful as vaccines for the protection from and/or treatment of HCMV infection. Said vaccines are useful as a monotherapy or a part of a therapeutic regime, said regime comprising administration of a second vaccine such as a polynucleotide, cell-based, protein or peptide-based vaccine.

8. 发明申请

WO2022173714A2 ANTIBODIES THAT BIND METAPNEUMOVIRUS, ANTIGENIC METAPNEUMOVIRUS PROTEINS, AND USES THEREOF 审中-公开
公开(公告)号：WO2022173714A2
公开(公告)日：2022-08-18
申请号：PCT/US2022/015565
申请日：2022-02-08
申请人： MERCK SHARP & DOHME LLC , CHEN, Zhifeng , COX, Kara, S. , FRIDMAN, Arthur , GALLI, Jennifer Dawn , SU, Hua-Poo , TANG, Aimin , VORA, Kalpit , WEN, Zhiyun , XIAO, Xiao , ZHANG, Lan
发明人： CHEN, Zhifeng , COX, Kara, S. , FRIDMAN, Arthur , GALLI, Jennifer Dawn , SU, Hua-Poo , TANG, Aimin , VORA, Kalpit , WEN, Zhiyun , XIAO, Xiao , ZHANG, Lan
IPC分类号： A61K39/395 , C07K16/1018 , C07K16/1027 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/92 , C07K2317/94
摘要： The present invention relates to anti-human metapneumovirus (hMPV) antibodies, as well as use of such antibodies in the treatment of viral infections. The invention also includes antigenic hMPV proteins and immunogenic compositions comprising such antigenic hMPV proteins, and the use of such antigenic hMPV proteins and related compositions for preventing or treating viral infection in a subject.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式